Literature DB >> 18177455

Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment.

Christine Carter-Kent1, Nizar N Zein, Ariel E Feldstein.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has emerged as a growing public health problem worldwide. NAFLD represents a wide spectrum of conditions ranging from fatty liver, that in general follows a benign nonprogressive clinical course, to nonalcoholic steatohepatitis (NASH), a serious form of NAFLD, that may progress to cirrhosis and end-stage liver disease. The mechanisms responsible for NAFLD development and disease progression remain incompletely understood, but are of great clinical interest as current therapies are limited. Future therapies will be predicted based upon the understanding of its pathogenesis. This review focuses on the growing evidence from both experimental and human studies suggesting a central role of cytokines in the pathogenesis of NAFLD. We review the role of cytokines as key regulators of insulin sensitivity and hepatic lipid overloading, liver injury and inflammation, and fibrosis and cirrhosis, with an emphasis on potential therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18177455     DOI: 10.1111/j.1572-0241.2007.01709.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  68 in total

1.  Selection of reference genes for qRT-PCR in high fat diet-induced hepatic steatosis mice model.

Authors:  Lingyan Xu; Xinran Ma; Bin Cui; Xiaoying Li; Guang Ning; Shu Wang
Journal:  Mol Biotechnol       Date:  2011-07       Impact factor: 2.695

2.  Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice.

Authors:  Wing-Kin Syn; Liu Yang; Dian Jung Chiang; Yue Qian; Youngmi Jung; Gamze Karaca; Steve S Choi; Rafal P Witek; Alessia Omenetti; Thiago A Pereira; Anna Mae Diehl
Journal:  Liver Int       Date:  2009-04-20       Impact factor: 5.828

Review 3.  What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 4.  Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease.

Authors:  Long-Xin Qiu; Tong Chen
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

5.  Murine gamma herpes virus 68 infection promotes fatty liver formation and hepatic insulin resistance in C57BL/6J mice.

Authors:  Lei Zhao; Ya-Xi Chen; Zac Varghese; Ai-Long Huang; Ren-Kuan Tang; Bei Jia; John F Moorhead; Jian-Ping Gong; Xiong Z Ruan
Journal:  Hepatol Int       Date:  2011-06-24       Impact factor: 6.047

6.  Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models.

Authors:  Y D Kim; Y H Kim; Y M Cho; D K Kim; S W Ahn; J M Lee; D Chanda; M Shong; C H Lee; H S Choi
Journal:  Diabetologia       Date:  2012-02-21       Impact factor: 10.122

7.  Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Rhiannon N Hardwick; April D Lake; Anika L Dzierlenga; John D Clarke; Michael J Goedken; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-12-08       Impact factor: 3.922

Review 8.  Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Lisa Longato; Ming Tong; Jack R Wands
Journal:  Curr Opin Investig Drugs       Date:  2009-10

Review 9.  The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Qing Liu; Stig Bengmark; Shen Qu
Journal:  Lipids Health Dis       Date:  2010-04-28       Impact factor: 3.876

10.  Inhibition of MEK/ERK1/2 Signaling Affects the Fatty Acid Composition of HepG2 Human Hepatic Cell Line.

Authors:  Bahman Yousefi; Masoud Darabi; Behzad Baradaran; Mahmoud Shekari Khaniani; Mohammad Rahbani; Maryam Darabi; Shabnam Fayezi; Amir Mehdizadeh; Negar Saliani; Maghsod Shaaker
Journal:  Bioimpacts       Date:  2012-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.